Ifosfamide

"Ifosfamide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.

Descriptor ID	D007069
MeSH Number(s)	D02.455.526.728.650.730.243.250 D02.705.672.500.243.250 D03.383.533.500
Concept/Terms	Ifosfamide Ifosfamide Isofosfamide Isophosphamide Iphosphamide Iso-Endoxan Iso Endoxan Holoxan Holoxan NSC-109,724 NSC-109,724 NSC 109,724 NSC109,724 NSC-109724 NSC 109724 NSC109724 Asta Z 4942 Asta Z 4942

Below are MeSH descriptors whose meaning is more general than "Ifosfamide".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Hydrocarbons [D02.455]
Hydrocarbons, Halogenated [D02.455.526]
Mustard Compounds [D02.455.526.728]
Nitrogen Mustard Compounds [D02.455.526.728.650]
Phosphoramide Mustards [D02.455.526.728.650.730]
Cyclophosphamide [D02.455.526.728.650.730.243]
Ifosfamide [D02.455.526.728.650.730.243.250]
Organophosphorus Compounds [D02.705]
Phosphoramides [D02.705.672]
Phosphoramide Mustards [D02.705.672.500]
Cyclophosphamide [D02.705.672.500.243]
Ifosfamide [D02.705.672.500.243.250]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Oxazines [D03.383.533]
Ifosfamide [D03.383.533.500]

Below are MeSH descriptors whose meaning is related to "Ifosfamide".

Below are MeSH descriptors whose meaning is more specific than "Ifosfamide".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Ifosfamide" by people in this website by year, and whether "Ifosfamide" was a major or minor topic of these publications.

Bar chart showing 21 publications over 16 distinct years, with a maximum of 2 publications in 2000 and 2004 and 2005 and 2011 and 2019

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	1	0	1
1997	0	1	1
1998	0	1	1
2000	1	1	2
2002	1	0	1
2003	0	1	1
2004	1	1	2
2005	0	2	2
2006	0	1	1
2007	1	0	1
2010	0	1	1
2011	0	2	2
2015	0	1	1
2017	0	1	1
2019	0	2	2
2023	0	1	1

Below are the most recent publications written about "Ifosfamide" by people in Profiles.

Bryan LJ, Casulo C, Allen PB, Smith SE, Savas H, Dillehay GL, Karmali R, Pro B, Kane KL, Bazzi LA, Chmiel JS, Palmer BA, Mehta J, Gordon LI, Winter JN. Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial. JAMA Oncol. 2023 05 01; 9(5):683-691.

View in: PubMed
Spunt SL, Million L, Chi YY, Anderson J, Tian J, Hibbitts E, Coffin C, McCarville MB, Randall RL, Parham DM, Black JO, Kao SC, Hayes-Jordan A, Wolden S, Laurie F, Speights R, Kawashima E, Skapek SX, Meyer W, Pappo AS, Hawkins DS. A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study. Lancet Oncol. 2020 01; 21(1):145-161.

View in: PubMed
Abuelgasim KA, Alzahrani M, Alsharhan Y, Khairi M, Hommady M, Gmati G, Salama H, Ali O, Alahmari B, Masuadi EM, Alaskar A, Alhejazi A, Damlaj M. Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma. Bone Marrow Transplant. 2019 07; 54(7):1168-1172.

View in: PubMed
Federico SM, McCarville MB, Shulkin BL, Sondel PM, Hank JA, Hutson P, Meagher M, Shafer A, Ng CY, Leung W, Janssen WE, Wu J, Mao S, Brennan RC, Santana VM, Pappo AS, Furman WL. A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma. Clin Cancer Res. 2017 Nov 01; 23(21):6441-6449.

View in: PubMed
Hattinger CM, Michelacci F, Sella F, Magagnoli G, Benini S, Gambarotti M, Palmerini E, Picci P, Serra M, Ferrari S. Excision repair cross-complementation group 1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy. Histopathology. 2015 Sep; 67(3):338-47.

View in: PubMed
Moretti VM, Crawford EA, Staddon AP, Lackman RD, Ogilvie CM. Early outcomes for malignant peripheral nerve sheath tumor treated with chemotherapy. Am J Clin Oncol. 2011 Aug; 34(4):417-21.

View in: PubMed
Fanale M, Fayad L, Pro B, Samaniego F, Liboon MJ, Nunez C, Horowitz S, Anderlini P, Popat U, Ji Y, Kwak LW, Younes A. Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma. Br J Haematol. 2011 Jul; 154(2):284-6.

View in: PubMed
Ogilvie CM, Crawford EA, Slotcavage RL, King JJ, Lackman RD, Hartner L, Staddon AP. Treatment of adult rhabdomyosarcoma. Am J Clin Oncol. 2010 Apr; 33(2):128-31.

View in: PubMed
Sehirli O, Sakarcan A, Velioglu-Og?n? A, Cetinel S, Gedik N, Yegen BC, Sener G. Resveratrol improves ifosfamide-induced Fanconi syndrome in rats. Toxicol Appl Pharmacol. 2007 Jul 01; 222(1):33-41.

View in: PubMed
Daw NC, Billups CA, Rodriguez-Galindo C, McCarville MB, Rao BN, Cain AM, Jenkins JJ, Neel MD, Meyer WH. Metastatic osteosarcoma. Cancer. 2006 Jan 15; 106(2):403-12.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement